Lanzhou Institute

Lanzhou Institute of Biological Products (LIBP) is a prominent Chinese biopharmaceutical enterprise and a key subsidiary of the China National Biotec Group (CNBG) under Sinopharm. Established in 1934, the institute has evolved into a major hub for the research, development, and large-scale production of vaccines, blood products, and therapeutic biologics. It is notably the exclusive manufacturer of Botulinum Toxin Type A (marketed as Hengli) in China, serving both medical and aesthetic markets. LIBP plays a critical role in China's national immunization program, supplying essential vaccines for diseases such as poliomyelitis, rotavirus, and influenza. The company maintains advanced GMP-certified facilities and continues to expand its portfolio through internal R&D and strategic collaborations within the Sinopharm ecosystem.